Company Performance - Seer, Inc. reported a quarterly loss of $0.34 per share, which was better than the Zacks Consensus Estimate of a loss of $0.40, but worse than the loss of $0.28 per share from a year ago, indicating a 21.4% increase in loss year-over-year [1] - The company posted revenues of $4 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.25%, but down from $4.44 million in the same quarter last year [2] - Over the last four quarters, Seer has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Market Comparison - Seer shares have lost approximately 1.3% since the beginning of the year, while the S&P 500 has gained 1.3%, indicating underperformance relative to the broader market [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $3.89 million, and for the current fiscal year, it is -$1.66 on revenues of $20.03 million [7] - The estimate revisions trend for Seer is mixed, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Seer belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Revenue Performance - Revenue for Q4 2024 was $4.0 million, a 10% decrease from $4.4 million in Q4 2023, primarily due to lower instrument sales and no grant revenue recognized[4]. - Full year 2024 revenue was $14.2 million, a 15% decrease from $16.7 million in 2023, attributed to lower product sales and no grant revenue recognized[8]. - Seer expects full year 2025 revenue to be in the range of $17 million to $18 million, representing a growth of 24% at the midpoint over full year 2024[11]. Profitability - Gross profit for Q4 2024 was $2.0 million with a gross margin of 51%[5]. - Gross profit for the full year 2024 was $7.1 million with a gross margin of 50%[9]. Expenses and Losses - Operating expenses for Q4 2024 were $25.5 million, a 5% increase from $24.2 million in Q4 2023, driven by higher laboratory expenses[5]. - Net loss for Q4 2024 was $21.7 million, compared to a net loss of $17.8 million in Q4 2023[7]. Instrument Shipments and Stock Repurchase - The company shipped 10 instruments in 2024, bringing cumulative instruments shipped to 72 as of December 31, 2024[6]. - Seer repurchased approximately 6.5 million shares of Class A common stock at an average cost of $1.82 per share during 2024, reducing shares outstanding by approximately 10%[6]. Cash Position - Cash, cash equivalents, and investments were approximately $300 million as of December 31, 2024[10].

Core Insights - Seer, Inc. reported a 10% decrease in revenue for Q4 2024, totaling $4.0 million compared to $4.4 million in Q4 2023, primarily due to lower instrument sales and no grant revenue recognized [4][7] - The company experienced a 15% decrease in total revenue for the full year 2024, amounting to $14.2 million, down from $16.7 million in 2023, attributed to lower product sales and lack of grant revenue [7][9] - Seer anticipates revenue growth for 2025, projecting full-year revenue between $17 million and $18 million, representing a 24% increase at the midpoint compared to 2024 [10] Financial Performance - Q4 2024 product revenue was $2.4 million, including $36 thousand from related party revenue, while service revenue was $1.6 million, with $353 thousand from related parties [4][5] - The gross profit for Q4 2024 was $2.0 million, resulting in a gross margin of 51% [5] - The net loss for Q4 2024 was $21.7 million, an increase from a net loss of $17.8 million in Q4 2023 [6] Annual Overview - For the full year 2024, product revenue was $10.2 million, including $1.5 million from related parties, while service revenue totaled $3.8 million, with $828 thousand from related parties [7][9] - The gross profit for the full year 2024 was $7.1 million, yielding a gross margin of 50% [8] - The total operating expenses for 2024 were $107.2 million, a decrease of 4% from $112.0 million in 2023 [8] Operational Highlights - Seer shipped 10 instruments in 2024, bringing the cumulative total to 72 as of December 31, 2024 [8] - The company repurchased approximately 6.5 million shares of Class A common stock at an average cost of $1.82 per share during 2024, reducing shares outstanding by about 10% [8] - Seer ended 2024 with approximately $300 million in cash, cash equivalents, and investments [9]

Core Insights - Seer, Inc. is participating in the TD Cowen 45th Annual Healthcare Conference in Boston, MA, highlighting its position in the life sciences sector [1] - The company will engage in a fireside chat on March 4, 2025, providing an opportunity for investors to gain insights into its operations and future plans [2] Company Overview - Seer is a life sciences company focused on developing transformative products for proteomics, specifically through its Proteograph™ Product Suite [3] - The Proteograph Product Suite includes engineered nanoparticles, consumables, automation instrumentation, and software designed for deep, unbiased proteomic analysis at scale [3] - The workflow is designed to be efficient and user-friendly, allowing integration into various laboratory settings, although it is intended for research use only and not for diagnostic procedures [3]

Core Insights - Seer, Inc. will present new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference, showcasing advancements in scalable deep cellular proteomics using the Proteograph™ Product Suite [1][2] - The seminar will feature a groundbreaking study on a co-delivery therapeutic platform targeting cancer vulnerabilities, utilizing both siRNA and mRNA therapeutics [1][5] - The study aims to simultaneously inactivate tumorigenic drivers and activate lost tumor suppressors, establishing a new strategy for treating a wide range of cancers [1][5] Company Overview - Seer, Inc. is a life sciences company focused on developing transformative products for proteomics, specifically through its Proteograph™ Product Suite, which integrates engineered nanoparticles, consumables, automation instrumentation, and software for deep proteomic analysis [10] - The Proteograph workflow is designed to be efficient and user-friendly, allowing for decentralized implementation in various laboratory settings [10] Event Details - The seminar titled "Transforming Cancer Research with Deep Cellular Proteomics" will be presented by Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School on February 25, 2025 [4] - Additional presentations at the conference will highlight the role of the Proteograph Product Suite in various proteomic studies, including tissue biology and cardiometabolic dysfunction [2][6]

Core Viewpoint - Seer, Inc. is set to report its financial results for Q4 and full year 2024 on February 27, 2025, with a conference call scheduled for 1:30 p.m. Pacific Time [1] Company Overview - Seer, Inc. is a life sciences company focused on developing transformative products for proteomics, specifically through its Proteograph™ Product Suite [3] - The Proteograph Product Suite includes engineered nanoparticles, consumables, automation instrumentation, and software for deep, unbiased proteomic analysis [3] - The workflow is designed to be efficient and user-friendly, allowing integration into various laboratory settings [3] - The Proteograph Product Suite is intended for research use only and is not meant for diagnostic procedures [3]

Company Participation - Seer, Inc. will participate in the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA [1] - The management is scheduled to present and engage in a Q&A session on January 15 at 3:00 p.m. Pacific Time [2] Product Overview - Seer is a life sciences company focused on developing transformative products for proteomics [3] - The Proteograph Product Suite includes engineered nanoparticles, consumables, automation instrumentation, and software for deep proteomic analysis [3] - The Proteograph workflow is designed to be efficient and user-friendly, allowing integration into various laboratory settings [3]

SEER commits to an aggressive decarbonization and carbon credit monetization program, starting with its current MV Technology solutions and its planned biocarbon production facilities both domestic and international. BROOMFIELD, CO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, has partnered with DevvStream, Inc., an emerging leader in carbon credit investi ...

DevvStream Enters Biogas Market via Partnership with Methane Renewable Energy LeaderDecember 12, 2024 7:30 AM EST | Source: DevvStream Corp.Carbon Management Program by SEER and DevvStream will be centered around biogas capture and carbon sequestration through biocarbon, or biochar, productionCompanies plan to leverage over 150 existing SEER-affiliate biogas installations across North America with numerous multinational utility companies, food processors, brewers, and agriculture firms as well ...

REDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it ranked No. 57 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. Seer grew 2,440% during this period. Seer’s President and CFO, David Horn, credits increased adoption ...